Concurrent Session 5: Melanoma & Other Skin Cancers

Date: Friday 29 September 2017
Time: 16.10-17.35
Room: Mozart Hall 1-3

Chairs: Andreas Baur, Lionel Larue

Concurrent talks are 8 minutes plus 2 minutes discussion.

Program

16.10-16.20

043 (Poster 533)
PDE4D is a therapeutic target in melanoma
N Dumaz,1,2 D Julie,1,2,3 S Becherirat,1,2 J Andre1,2 and C Lebbe1,2,3 1 INSERM U976, Paris, France, 2 UMRS 976, University Paris Diderot, Paris, France and 3 Dermatology Department, Saint Louis Hospital, Paris, France
16.20-16.30 044 (Poster 532)
Variable but distinct metabolic signature in malignant melanoma
R Lang,1 RG Feichtinger,5 R Geilberger,5 F Rathje,5 JA Mayr,2 W Sperl,2 JW Bauer,1 C Hauser-Kronberger,3 M Emberger4 and B Kofler5 1 Department of Dermatology, Paracelsus Medical University Salzburg, Salzburg, Austria, 2 Department of Pediatrics, Paracelsus Medical University Salzburg, Salzburg, Austria, 3 Institute of Pathology, Paracelsus Medical University Salzburg, Salzburg, Austria, 4 Laboratory for Pathology Weger/Emberger, Salzburg, Austria and 5 Department of Pediatrics, Research Program for Receptor Biochemistry and Tumor Metabolism, Paracelsus Medical University Salzburg, Salzburg, Austria
16.30-16.40 045 (Poster 522)
N-Oct3 is a tumor suppressor and acts as a radioprotector
L Larue Institut Curie, Orsay, France
16.40-16.50 046 (Poster 529)
Microphthalmia-associated transcription factor regulates dynamic melanoma heterogeneity
NK Haass,1,2 L Spoerri,1 CA Tonnessen,1 KA Beaumont,2 DS Hill,2 RJ Jurek,2 SM Daignault,1 F Ahmed,1 AG Smith1 and W Weninger2 1 University of Queensland Diamantina Institute, Woolloongabba, QLD, Australia and 2 Centenary Institute, Sydney, NSW, Australia
16.50-17.00 047 (Poster 538)
Transdifferentiation of melanoma cells by the reprogramming factors lose malignant nature in vitro and in vivo
M Takaishi and S Sano Dermatology, Kochi Medical School, Nankoku, Japan
17.00-1710 048 (Poster 540)
Tumor cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma
P Riihilä,1,2 K Viiklepp,1,2 L Nissinen,1,2 M Farshchian,1,2 M Kallajoki,3 A Kivisaari,1,2 S Meri,4 R Grénman,5 S Peltonen,1 J Peltonen6 and V Kähäri1,2 1 Department of Dermatology, University of Turku and Turku University Hospital, Turku, Finland, 2 MediCity Research Laboratory, University of Turku, Turku, Finland, 3 Department of Pathology, Turku University Hospital, Turku, Finland, 4 Haartman Institute, University of Helsinki, Helsinki, Finland, 5 Department of Otorhinolaryngology - Head and Neck Surgery, Turku University Hospital, Turku, Finland and 6 Department of Anatomy and Cell Biology, University of Turku, Turku, Finland
17.10-17.20 049 (Poster 537)
Accelerated endogenous mutation rate drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa
RJ Cho,2 V Atanasova,1 N den Breems,3 L Alexandrov,4 K Tsai5 and A South1 1 Thomas Jefferson University, Philadelphia, PA, 2 UCSF, San Francisco, CA, 3 University of Auckland, Auckland, New Zealand, 4 Los Alamos National Laboratory, Los Alamos, NM and 5 Moffitt Cancer Center, Tampa Bay, FL
17.20-17.30 050 (Poster 528)
MicroRNA-130a (miR-130a) regulates self-renewal capacity and tumor growth in cutaneous squamous cell carcinoma
W Lohcharoenkal, K Das Mahapatra, N Xu Landén, E Sonkoly and A Pivarcsi Department of Medicine, Unit of Dermatology and Venereology, Karolinska Institutet, Stockholm, Sweden